伊立替康联合顺铂治疗晚期非小细胞肺癌的临床观察  

Clinical Observation of Irinotecan plus Cisplatin for Advanced Non-small Cell Lung Cancer

作　　者：赵文英[1] 陈冬云[1] 叶晓兵[1] 陈景华[1] 

机构地区：[1]皖南医学院弋矶山医院肿瘤内科,安徽芜湖241000

出　　处：《肿瘤基础与临床》2013年第2期107-110,共4页journal of basic and clinical oncology

摘　　要：目的评价伊立替康(CPT-11)联合顺铂(DDP)(IP方案)治疗晚期非小细胞肺癌(NSCLC)的疗效和毒副反应。方法入组31例晚期NSCLC患者均接受IP方案治疗:CPT-11 100 mg·m-2,静脉滴注90min,d1,8;DDP 75 mg·m-2,静脉滴注,d1～3,分3次给药,21 d为1周期。结果全组无CR病例,PR 8例(25.8%),SD 17例(54.8%),PD 6例(19.4%),有效率(RR)为25.8%。初治者RR为31.6%(6/19),复治者RR为16.7%(2/12)。中位疾病进展时间为204 d。Ⅲ、Ⅳ度毒副反应主要为粒细胞减少、脱发、腹泻和恶心呕吐。结论 IP方案治疗晚期NSCLC有效,且患者耐受性良好。Objective To evaluate the efficacy and toxicities of irinotecan （ CPT-11 ） combined with cisplatin （DDP） （ IP regimen） in the treatment of patients with advanced non-small cell lung cancer （NSCLC）. Methods Thirty one patients with advanced NSCLC received the IP regimen chemotherapy： CPT-11 100 mg·m-2, intrave- nously guttae, d1,8 , DDP 75 mg·m-2 was divided into 3 days,intravenously guttae, dl.3, every 21 days was a cycle. Results Of the 31 patients, no CR was observed, PR in the 8 patients （25.8%）, SD in the 17 patients （54.8%）, PD in the 6 patients （ 19.4% ） ,the response rate （RR） was 25.8%. The RR was 31.6% （6/19） of the initial treatment patients, and was 16.7% （2/12） of the retreatment patients. The median time to tumor progression was 204 days. The main toxicities with grade IU-IV were neutropenia, alopecia, diarrhea, nausea and vomiting. Conclusion IP regimen is effective for the patients with advanced NSCLC, and the toxicities can be tolerated.

关 键 词：伊立替康 顺铂 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]